SITC 2021 | SEA-TGT: a novel drug for patients with solid tumors and lymphomas

Diwakar Davar, MD, University of Pittsburgh, Pittsburgh, PA, explains the mechanism of action of SEA-TGT, a human, non-fucosylated anti-T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) monoclonal antibody with enhanced immune-effector function currently under investigation for the treatment of solid tumors and lymphomas. SGNTGT-001 is a Phase I study (NCT04254107) evaluating the safety of SEA-TGT in patients with advanced malignancies. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.